deferasirox has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, X; Song, P; Wang, Y; Wu, X; Yan, J; Zhang, H; Zheng, R | 1 |
| Mirian, M; Rostami, M; Varshosaz, J; Veisi, H | 1 |
2 other study(ies) available for deferasirox and Melanoma
| Article | Year |
|---|---|
Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma.
Topics: Animals; B7-H1 Antigen; Cell Line, Tumor; Deferasirox; Down-Regulation; Doxorubicin; Immunotherapy; Liposomes; Major Histocompatibility Complex; Melanoma; Mice; Nanoparticles; Phosphatidylinositol 3-Kinases; Tumor Microenvironment; Up-Regulation | 2022 |
Thermosensitive TMPO-oxidized lignocellulose/cationic agarose hydrogel loaded with deferasirox nanoparticles for photothermal therapy in melanoma.
Topics: Deferasirox; Humans; Hydrogels; Iron; Melanoma; Nanoparticles; Nuclear Proteins; Photothermal Therapy; Polymers; Pyrroles; Sepharose; Thymopoietins | 2023 |